Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by Taxol (AC-T) to that of adriamycin and cyclophosphamide followed by Taxol plus Herceptin (AC-T+H) in node-positive breast cancer patients who have tumors that overexpress HER2.

Next Previous
Trial Profile

A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by Taxol (AC-T) to that of adriamycin and cyclophosphamide followed by Taxol plus Herceptin (AC-T+H) in node-positive breast cancer patients who have tumors that overexpress HER2.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 06 Jun 2023 Results of pooled analysis from NCT00045032, ISRCTN76560285, NCT00005970, NCT00004067, NCT00054587, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 28 Apr 2021 Status changed from active, no longer recruiting to completed.
    • 28 Aug 2020 Results (n=1770) of pooled analysis assessing long-term outcomes (iDFS and OS) of patients from APT trial (NCT00542451) vs matched external controls from five studies ((BCIRG 006 [NCT00021255], NSABP-B31 [NCT00004067], HERA [NCT00045032], N-9831 [NCT00005970], and APHINITY [NCT01358877])), published in the Annals of Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top